JT010
Based on 4 publication(s) in Google Scholar
JT010 is a covalent and site-selective TRPA1 agonist. JT010 can be used in myocardial infarction research.
For research use only. We do not sell to patients.
- Purity: 99.48%
- CAS No.: 917562-33-5
- Formula: C16H19ClN2O3S
- Molecular Weight:354.85
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
Publications Citing Use of MedChemExpress (MCE) JT010
More
Biological Activity
EC50: 0.65 nM (TRPA1)[1]
JT010 (1-40 μM, 10 min before activation of cells) shows a concentration-dependent inhibitory effect on T-cell receptor (TcR)-induced Ca2+ signals in CD4+ T lymphocytes[2].
JT010 (0.3-100 nM) activates TRPA1 in human cells HEK-hTRPA1[3].
JT010 (50 nM) induces activation of TRPA1 ion currents in human lung tissue but also did not modify fibrosis relevant gene expression in the presence of TGFβ1[4].
JT010 (100 nM) shows a mean ATP concentration of 0.52 μM in DRGN cells[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 917562-33-5
-
Appearance Solid
-
Molecular Weight 354.85
-
Formula C16H19ClN2O3S
-
Color Light yellow to yellow
-
SMILES
O=C(N(C1=NC(C2=CC=C(OC)C=C2)=CS1)CCCOC)CCl
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (4)
-
Journal Impact Factor
-
Most Recent
-
-
ACS Appl Mater Interfaces
Enhancing Photodynamic Therapy Efficacy via Photo-Triggered Calcium Overload and Oxygen Delivery in Tumor Hypoxia Management. [Abstract]2025 Feb 5;17(5):8403-8416. PMID: 39853325 -
J Membr Biol
Transient Receptor Potential Ankyrin 1 Contributes to Lysophosphatidylcholine-Induced Intracellular Calcium Regulation and THP-1-Derived Macrophage Activation. [Abstract]2020 Feb;253(1):43-55. PMID: 31820013 -
bioRxiv
Agonism of mosquito and human transient receptor potential ankyrin 1 (TRPA1) channels by the natural drimane sesquiterpene cinnamodial. [Abstract]2025 Dec 11:2025.12.09.693172. PMID: 41427278
Solvent & Solubility
DMSO : 100 mg/mL (281.81 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (7.05 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (278 KB)
-
SDS (555 KB)
- English - EN (555 KB)
- Français - FR (555 KB)
- Deutsch - DE (555 KB)
- Norwegian - NO (555 KB)
- Español - ES (555 KB)
- Swedish - SV (555 KB)
- Italian - IT (555 KB)
- Korean - KR (555 KB)
- Portuguese - PT (555 KB)
-
Handling Instructions (2659 KB)
References
[1]. Takaya J, et al. A Potent and Site-Selective Agonist of TRPA1. J Am Chem Soc. 2015 Dec 23;137(50):15859-64. [Content Brief]
[2]. Szabó K, et al. TRPA1 Covalent Ligand JT010 Modifies T Lymphocyte Activation. Biomolecules. 2024 May 28;14(6):632. [Content Brief]
[3]. Matsubara M, et al. Potent Activation of Human but Not Mouse TRPA1 by JT010. Int J Mol Sci. 2022 Nov 18;23(22):14297. [Content Brief]
[4]. Virk HS, et al. TGFβ1 induces resistance of human lung myofibroblasts to cell death via down-regulation of TRPA1 channels. Br J Pharmacol. 2021 Aug;178(15):2948-2962. [Content Brief]
[5]. Singh U, et al. Investigation of the Pathomechanism of Chronic Cough Using an In Vitro Approach. Clin Exp Allergy. 2025 Jan 21. [Content Brief]
[6]. Hoebart C, Kiss A, Pilz PM, Szabo PL, Podesser BK, Fischer MJM, Heber S. TRPA1 as Target in Myocardial Infarction. Int J Mol Sci. 2023 Jan 28;24(3):2516. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.8181 mL | 14.0905 mL | 28.1809 mL | 70.4523 mL |
| 5 mM | 0.5636 mL | 2.8181 mL | 5.6362 mL | 14.0905 mL | |
| 10 mM | 0.2818 mL | 1.4090 mL | 2.8181 mL | 7.0452 mL | |
| 15 mM | 0.1879 mL | 0.9394 mL | 1.8787 mL | 4.6968 mL | |
| 20 mM | 0.1409 mL | 0.7045 mL | 1.4090 mL | 3.5226 mL | |
| 25 mM | 0.1127 mL | 0.5636 mL | 1.1272 mL | 2.8181 mL | |
| 30 mM | 0.0939 mL | 0.4697 mL | 0.9394 mL | 2.3484 mL | |
| 40 mM | 0.0705 mL | 0.3523 mL | 0.7045 mL | 1.7613 mL | |
| 50 mM | 0.0564 mL | 0.2818 mL | 0.5636 mL | 1.4090 mL | |
| 60 mM | 0.0470 mL | 0.2348 mL | 0.4697 mL | 1.1742 mL | |
| 80 mM | 0.0352 mL | 0.1761 mL | 0.3523 mL | 0.8807 mL | |
| 100 mM | 0.0282 mL | 0.1409 mL | 0.2818 mL | 0.7045 mL |